Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213529 | 0.84 | MAPT (0.39) | HPGDSMN1; SMN2KDM4EPOLBCA1 | |
| SCHEMBL3944635 | 0.81 | HPGD (0.49) | ERN1HPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL9260252 | 0.80 | CA1 (0.57) | ERN1HPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30739961 | 0.80 | CA1 (0.57) | ERN1HPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL30593089 | 0.80 | ALDH1A1 (0.46) | HPGDALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL23748164 | 0.80 | HTR2C (0.39) | ERN1HPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL11293049 | 0.80 | CXCR5 (0.43) | HPGDALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL23748226 | 0.80 | ALDH1A1 (0.46) | HPGDALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL4438654 | 0.80 | ERN1 (0.49) | ERN1HPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL2032770 | 0.79 | ERN1 (0.47) | ERN1HPGDALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-117915918-A | Soluble adenylate cyclase (sAC) inhibitors and uses thereof | 康奈尔大学 | 2024-04-19 | — | — | CN | disclosed |
| EP-4329762-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | Cornell University (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2022232259-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3864020-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | Janssen BioPharma, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| US-9663536-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-30 | — | — | US | disclosed |
| US-9663536-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-30 | — | — | US | disclosed |
| US-9663536-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-30 | — | — | US | disclosed |
| EP-2970301-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2970301-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| EP-2970301-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002263-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160002263-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20160002263-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| WO-2014164428-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164428-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | ACE, PNP, FEN1 | ERN1 468/4885HPGD 1171/4885ALDH1A1 2073/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | ERN1 3206/4885HPGD 917/4885ALDH1A1 638/4885 |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | ACE, FEN1, PNP | ERN1 543/4885HPGD 1024/4885ALDH1A1 1487/4885 |
| US-20160002263-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, EFTUD2, SARS1 | ERN1 336/4885HPGD 1739/4885ALDH1A1 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.